On february 11, 2025, the food and drug administration approved mirdametinib (gomekli, springworks therapeutics, inc.), a kinase inhibitor, for adult and pediatric patients 2 years of. [1] mirdametinib is a kinase inhibitor. Gomekli (mirdametinib) 1 mg and 2 mg capsules contain 1 mg and 2 mg mirdametinib, respectively, in gelatin capsule and the following inactive ingredients:
Restored Republic via a GCR Update as of March 29, 2024 Restored
Indications, dosage, adverse reactions and pharmacology. [1][4] it is taken by. This era, which began at the close of the last ice age, represents.
Many of these pillars are decorated with anthropomorphic details,.
Mirdametinib, sold under the brand name gomekli, is a medication used for the treatment of people with neurofibromatosis type 1. Gomekli package insert / prescribing information for healthcare professionals. Gomekli capsules and tablets for oral suspension contain mirdametinib, a kinase inhibitor.
